文献速递支持与姑息治疗

EORTC QLQ-SURV100癌症幸存者生活质量问卷国际IV期验证研究

International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100.
PubMed 文献 · Eur J Cancer · 2026-07-22

本研究为国际IV期实地研究,在21国46中心1480例无病生存1-10年的癌症幸存者中验证EORTC QLQ-SURV100问卷。结果显示该问卷结构效度良好(CFI=0.951,TLI=0.944,RMSEA=0.046),重测信度ICC多数>0.7,已知组比较支持构念效度,DIF分析示轻微跨文化条目偏倚但无性别相关DIF,IRT分析未发现冗余条目。

要点

  • QLQ-SURV100在多种癌症幸存者中显示良好结构效度与重测信度。
  • 问卷对治疗、合并症、年龄、性别和教育程度具有敏感性。
  • 跨文化条目偏倚轻微,性别间测量等价性成立。

核心结论

  • EORTC QLQ-SURV100在无病生存癌症幸存者中显示满意的结构效度、重测信度和构念效度,条目冗余有限,在性别和语言组间具有测量等价性。

研究设计与样本

  • 国际IV期实地验证研究,纳入21国46中心1480例完成主要治疗1-10年且无活动性疾病证据的癌症幸存者(31%乳腺癌,23%结直肠癌,22%前列腺癌,24%其他癌症)。

主要发现

  • 验证性因子分析示结构效度强:CFI=0.951,TLI=0.944,RMSEA=0.046,多数标准化因子载荷>0.7。
  • 重测信度ICC在35个量表中27个>0.7,34个>0.6。
  • 已知组比较支持多数假设,确认对治疗、合并症、年龄、性别和教育程度的敏感性。
  • DIF分析示轻微跨文化条目偏倚,但无性别相关DIF;IRT分析未发现冗余条目。

关键数值与推荐

  • 结构效度指标:CFI=0.951,TLI=0.944,RMSEA=0.046。
  • 重测信度:35个量表中27个ICC>0.7,34个ICC>0.6。
  • 多数标准化因子载荷>0.7。

临床怎么用

  • QLQ-SURV100可用于评估多种癌症无病生存者的健康相关生活质量,涵盖慢性躯体问题及多癌种、多语言文化背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cancer survivors face unique and persistent health-related quality of life (HRQoL) challenges. Existing HRQoL questionnaires for survivors lack content regarding chronic physical issues and have typically included limited cancer types and languages/cultures, affecting breadth of content and generalisability. We developed and validated the EORTC QLQ-SURV100, a questionnaire to assess HRQoL in disease-free survivors of diverse cancers. A conceptual framework of HRQoL in cancer survivors, developed in previous study phases and conceptualised as survivors' self-reported physical, mental and social functioning and well-being, formed the basis for questionnaire content. METHODS: The QLQ-SURV100 was administered to 1480 participants across 46 centres in 21 countries (31% breast cancer, 23% colorectal, 22% prostate, 24% other cancers), who had completed primary treatment 1-10 years earlier and had no evidence of active disease. Structural validity of the 21 multi-item questionnaire scales was assessed via confirmatory factor analysis; test-retest reliability via intraclass correlation coefficients (ICCs); construct validity through known-group comparisons; and cross-cultural validity and sex invariance through differential item functioning (DIF). Item response theory (IRT) analyses evaluated item redundancy and performance. RESULTS: The QLQ-SURV100 showed strong structural validity (Comparative Fit Index = 0.951; Tucker-Lewis Index = 0.944; Root Mean Square Error of Approximation = 0.046), with most standardised factor loadings > 0.7. Test-retest ICCs exceeded 0.7 for 27 of 35 scales and 0.6 for 34 scales. Known-groups analyses supported most hypotheses, confirming sensitivity to treatment, comorbidity, age, sex, and education. DIF analysis indicated minor cross-cultural item bias, but no sex-related DIF. IRT analysis found no redundant items. CONCLUSIONS: The EORTC QLQ-SURV100 showed satisfactory structural validity, test-retest reliability and construct validity; limited item redundancy; and measurement invariance across the sex and language groups examined.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fox L, van Leeuwen M, Jones JM, et al. International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100. Eur J Cancer. 2026. PMID: 42541912. doi:10.1016/j.ejca.2026.116959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。